VERTEX PHARMACEUTICALS INC / MA Increase (Decrease) in Accrued Liabilities
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Increase (Decrease) in Accrued Liabilities of $122.20 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in accrued liabilities for fiscal 2020 was $122.20M, a 29.32% decline from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in accrued liabilities for fiscal 2019 was $172.88M, a 42.90% decline from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in accrued liabilities for fiscal 2018 was $302.75M, a 18.64% increase from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in accrued liabilities for fiscal 2017 was $255.18M.
| Period end | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|
| 2020-12-31 | $122.20M 10-K · filed 2021-02-11 |
| 2019-12-31 | $172.88M 10-K · filed 2021-02-11 |
| 2018-12-31 | $302.75M 10-K · filed 2021-02-11 |
| 2017-12-31 | $255.18M 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |